BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 17442100)

  • 1. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
    Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
    BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
    Kontoyiannis DP; Hachem R; Lewis RE; Rivero GA; Torres HA; Thornby J; Champlin R; Kantarjian H; Bodey GP; Raad II
    Cancer; 2003 Jul; 98(2):292-9. PubMed ID: 12872348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
    Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
    Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
    Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical characteristics and efficacy of anti-Aspergillus therapy in patients with hematological malignancies and invasive aspergillosis].
    Li Y; Gao L; Wang LL; Wang QS; Li HH; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1289-93. PubMed ID: 22040990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
    Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin for the treatment of invasive fungal disease in hematological patients (ProCAS Study).
    Jarque I; Tormo M; Bello JL; Rovira M; Batlle M; Julià A; Tabares S; Rivas C; Fernández-Sevilla A; García-Boyero R; Debén G; González-Campos J; Capote FJ; Sanz MA;
    Med Mycol; 2013 Feb; 51(2):150-4. PubMed ID: 22712457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
    Aliff TB; Maslak PG; Jurcic JG; Heaney ML; Cathcart KN; Sepkowitz KA; Weiss MA
    Cancer; 2003 Feb; 97(4):1025-32. PubMed ID: 12569602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful antifungal combination therapy with voriconazole and caspofungin.
    Schuster F; Moelter C; Schmid I; Graubner UB; Kammer B; Belohradsky BH; Führer M
    Pediatr Blood Cancer; 2005 Jun; 44(7):682-5. PubMed ID: 15700260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study.
    Rubio PM; Sevilla J; González-Vicent M; Lassaletta A; Cuenca-Estrella M; Díaz MA; Riesco S; Madero L
    J Pediatr Hematol Oncol; 2009 Sep; 31(9):642-6. PubMed ID: 19684521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
    Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
    Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
    Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
    Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
    Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
    Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
    Viscoli C; Herbrecht R; Akan H; Baila L; Sonet A; Gallamini A; Giagounidis A; Marchetti O; Martino R; Meert L; Paesmans M; Ameye L; Shivaprakash M; Ullmann AJ; Maertens J;
    J Antimicrob Chemother; 2009 Dec; 64(6):1274-81. PubMed ID: 19841031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
    Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
    Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland.
    Anttila VJ; Salonen J; Ylipalosaari P; Koivula I; Riikonen P; Nikoskelainen J
    Clin Microbiol Infect; 2007 Jun; 13(6):606-12. PubMed ID: 17378926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis.
    Klont RR; Mennink-Kersten MA; Ruegebrink D; Rijs AJ; Blijlevens NM; Donnelly JP; Verweij PE
    Clin Infect Dis; 2006 Aug; 43(3):e23-5. PubMed ID: 16804836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
    Denning DW; Marr KA; Lau WM; Facklam DP; Ratanatharathorn V; Becker C; Ullmann AJ; Seibel NL; Flynn PM; van Burik JA; Buell DN; Patterson TF
    J Infect; 2006 Nov; 53(5):337-49. PubMed ID: 16678903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.